23 Jan 2026 | 5 Mins Read
ICICI Securities recommends buying Tatva Chintan Pharma Chem
Flipitmoney
Tatva Chintan Pharma Chem's (TATVA) Q3FY26 results showed recovery in SDA and PASC segments. SDA revenue grew 132% YoY due to stable prices and new volumes. PASC is poised for growth from large agro-intermediates and Pharma intermediate's commercialisation in H2FY27. EBITDA estimates cut by 2-3% but Target Price raised to INR 1,955, with a 'BUY' rating.